EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Polypharmacy and drug interactions in pediatric prescribing

Meet Patel, Darshan Dave, Apexa Shukla, Aastha Patel, Amit Shah

Hospital Pharmacology - International Multidisciplinary Journal · 2025 · 12 (1) · 1620-1627

DOI: 10.5937/hpimj2501620p ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hospital Pharmacology - International Multidisciplinary Journal, 2025. Verfasst von Meet Patel und 4 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction:The study addresses the escalating concern of pediatric polypharmacy and potential drug-drug interactions (pDDIs) in the context of pediatric care, where uncertainties regarding medication combinations and safety checks are prevalent.Despite the rising incidence of chronic diseases among children, limited research exists on pediatric polypharmacy, with varying prevalence rates reported globally.

Aim

The Aim of the study is to estimate the prevalence of polypharmacy, identify associated factors, and assess potential drug-drug interactions in pediatric prescribing. Material and Methods:This was an academic, prospective, observational and cross-sectional study.Ethical clearance was obtained, and a sample size of 117 pediatric patients was determined based on existing prevalence rates.Data collection involved reviewing treatment records and conducting personal interviews, focusing on socio-demographic profiles, symptoms, and drug therapy.Polypharmacy was defined as the simultaneous use of two or more different medications, and potential drug-drug interactions were assessed using the Drug Interaction Checker by Medscape.

Results

Analysis of 117 pediatric patients revealed a high prevalence of polypharmacy (93.16%), with the majority prescribed 3-4 drugs concurrently.Potential drug-drug interactions were observed in 14% of prescriptions, primarily categorized as "Monitor Closely".Albuterol and xylometazoline emerged as the most common drug pair associated with moderate pDDIs.Multivariate logistic regression identified polypharmacy as a significant predictor for pDDIs (p < 0.00017), while age, gender, and weight showed no significant associations. Conclusion:The study underscores the significant prevalence of pediatric polypharmacy and potential drug-drug interactions, highlighting the need for improved prescribing practices and medication safety measures in pediatric care.Addressing these concerns requires ongoing research and development efforts to enhance therapeutic efficacy and safety for pediatric patients.

Zitieren

APA

Patel, M., Dave, D., Shukla, A., Patel, A., & Shah, A. (2025). Polypharmacy and drug interactions in pediatric prescribing. Hospital Pharmacology - International Multidisciplinary Journal, 12(1), 1620-1627. https://doi.org/10.5937/hpimj2501620p

Vancouver

Patel M, Dave D, Shukla A, Patel A, Shah A. Polypharmacy and drug interactions in pediatric prescribing. Hospital Pharmacology - International Multidisciplinary Journal. 2025;12(1):1620-1627. doi:10.5937/hpimj2501620p

BibTeX
@article{Patel2025,
  author = {Patel, Meet and Dave, Darshan and Shukla, Apexa and Patel, Aastha and Shah, Amit},
  title = {Polypharmacy and drug interactions in pediatric prescribing},
  journal = {Hospital Pharmacology - International Multidisciplinary Journal},
  year = {2025},
  volume = {12},
  number = {1},
  pages = {1620--1627},
  doi = {10.5937/hpimj2501620p}
}
Kostenlos starten →